Antheia Celebrates Milestone With First Commercial Thebaine Delivery

Antheia, a pioneer in reshaping pharmaceutical ingredient supply chains, announced its successful delivery of an initial commercial order of thebaine to a major pharmaceutical client. This full-scale order marks a significant milestone, as thebaine will be used in producing essential medicines. The announcement highlights Antheia’s capability to biomanufacture pharmaceutical ingredients at commercial scale, having met all regulatory requirements for its biosynthetically produced products.

Richard Sherwin, SVP of Commercialization at Antheia, said in a statement, “Completing our first commercial delivery of thebaine is a landmark moment for us as a company and represents a tangible step toward our mission to transform supply chains for essential medicines. Today’s announcement further cements biomanufacturing’s role in the pharmaceutical industry and this is just the beginning – we look forward to fulfilling additional near-term orders and partnering with more companies to offer a more resilient and reliable supply for key starting materials (KSMs) and active pharmaceutical ingredients (APIs).”

Antheia’s flagship product, thebaine, serves as a key starting material (KSM) in manufacturing crucial medicines for post-surgical and severe acute pain relief, overdose reversal, and addiction treatment. Partnering with Olon, a European CDMO, Antheia has been producing thebaine at a commercial scale and is now actively working on a U.S. production strategy to meet domestic demand for thebaine and other KSMs and APIs.

In parallel, Antheia is making strides in developing additional pipeline products, including oripavine and scopolamine. Moving forward, the company aims to expand its commercial reach by launching more products and building partnerships with top-tier U.S. and global customers.